Physician profile

Kevin John Lorentsen

Hematology & Oncology · Chambersburg, PA

NPI 1700878683

$340.00

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$83.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $112.96 2019
Sobi, INC $83.82 2023
E.R. Squibb & Sons, L.L.C. $30.70 2019
Seagen INC. $20.92 2019
Heron Therapeutics, INC. $18.79 2019
Abbvie INC. $16.03 2019
Coherus Oncology, INC. $14.36 2020
Lilly USA, LLC $12.67 2019
Acrotech Biopharma INC. $11.97 2021
Astellas Pharma US INC $11.53 2019
Janssen Pharmaceuticals, INC $6.25 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kevin John Lorentsen

$340.00

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Biotech, INC.

https://glasscript.com/doctor/1265240/kevin-john-lorentsen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.